Brief: AstraZeneca says Tozorakimab significantly and meaningfully reduces COPD exacerbations in Phase III trials
08/09/2026 12:45
BRIEF-AstraZeneca says Tozorakimab significantly and meaningfully reduces COPD exacerbations in Phase III trials Sept 8 (Reuters) - AstraZeneca PLC AZN.L:
ASTRAZENECA- TOZORAKIMAB 300MG SHOWS REDUCTION IN MODERATE, SEVERE COPD EXACERBATIONS IN OVERALL CURRENT, FORMER SMOKER POPULATION BY 30% IN OBERON
ASTRAZENECA- TOZORAKIMAB 300MG SHOWS REDUCTION IN MODERATE, SEVERE COPD EXACERBATIONS IN PRIMARY POPULATION OF FORMER SMOKERS BY 29% IN OBERON TRIAL
ASTRAZENECA- TOZORAKIMAB 300MG SHOWS REDUCTION IN MODERATE, SEVERE COPD EXACERBATIONS IN PRIMARY POPULATION OF FORMER SMOKERS BY 34% IN TITANIA TRIAL
ASTRAZENECA- TOZORAKIMAB 300MG SHOWS REDUCTION IN MODERATE, SEVERE COPD EXACERBATIONS IN OVERALL CURRENT, FORMER SMOKER POPULATION BY 29% IN TITANIA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines